Cosmo Pharmaceuticals N.V. (0RGI.L)
| Previous close | 51.35 |
| Open | 52.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 52.70 - 53.10 |
| 52-week range | 52.70 - 53.10 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 782.274M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousCOSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA 03.05.2022 / 06:00 Press Release (PDF)Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.Eleview(R) is a sub
- EQS Group
COSMO ANNOUNCES FULL-YEAR RESULTS 2021;CONFIRMS BEATING GUIDANCE
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results23-March-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.9
- EQS Group
First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with Artificial Intelligence (AI) technology versus standard colonoscopy
Cosmo Pharmaceuticals N.V. / Key word(s): Study results18-March-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland - 18 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announced that Medtronic on 16 March 2022 issued the following release:Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, intern
